Post-marketing study of cilostazol: study to confirm efficacy in preventing recurrent cerebral infarction in comparison with aspirin.

Trial Profile

Post-marketing study of cilostazol: study to confirm efficacy in preventing recurrent cerebral infarction in comparison with aspirin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CSPS-II
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 13 May 2016 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2010 Results were presented in a late-breaking science session at the American Stroke Association's International Stroke Conference, according to an Otsuka Pharmaceutical media release (9110055) and an American Stroke Association media release (9109952).
    • 23 Apr 2008 Changed patient number from 2600 to 2800. Update from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top